

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/849,044	05/04/2001	Dusan Pavenik	PA-5252-RFB	9073
75	90 10/05/2006		EXAM	INER
Richard J. Godlewski			STEWART, ALVIN J	
Patent Attorney P.O. Box 2269			ART UNIT	PAPER NUMBER
Bloomington, IN 47402-2269			3738	
			DATE MAILED: 10/05/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

				•			
		Application No.	Applicant(s)				
		09/849,044	PAVCNIK ET AL.				
	Office Action Summary	Examiner	Art Unit	-			
		Alvin J. Stewart	3738				
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the	correspondence address				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL CHEVER IS LONGER, FROM THE MAILING D nsions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. Depriod for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  ATE OF THIS COMMUNICATION  ATE OF THIS COMMUNICATION  BY A STATE OF THIS COMMUNIC	ON. timely filed om the mailing date of this communication NED (35 U.S.C. § 133).				
Status			•				
1)⊠	Responsive to communication(s) filed on <u>03 A</u>	pril 2006.					
2a)⊠	This action is FINAL. 2b) ☐ This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11,	453 O.G. 213.				
Dispositi	ion of Claims		(				
4) 🖂	Claim(s) 1 and 3-9 is/are pending in the applic	cation.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	Claim(s) is/are allowed.						
6)⊠	Claim(s) 1, 3-9 is/are rejected.						
7)	Claim(s) is/are objected to.						
8) 🗌	Claim(s) are subject to restriction and/o	or election requirement.					
Applicati	ion Papers						
9)	The specification is objected to by the Examine	er.					
10)🛛	The drawing(s) filed on 07 July 2002 is/are: a)	⊠ accepted or b) □ objected to	by the Examiner.				
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).				
•	Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is	objected to. See 37 CFR 1.121(	d).			
11)	The oath or declaration is objected to by the E	xaminer. Note the attached Office	ce Action or form PTO-152.				
Priority ι	under 35 U.S.C. § 119						
-	Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119	(a)-(d) or (f).				
a)	☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documen		-ti Ni-				
	2. Certified copies of the priority document	• • • • • • • • • • • • • • • • • • • •					
	<ol> <li>Copies of the certified copies of the price application from the International Burea</li> </ol>		ved in this National Stage				
* 5	See the attached detailed Office action for a list	` ''	ved				
	see the attached detailed embe action for a list	of the certified copies flot recei					
Attachmen	• •						
1) Notice	e of References Cited (PTO-892)	4) Interview Summa					
	e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail 5) Notice of Informa	Patent Application (PTO-152)				
. —	r No(s)/Mail Date	6) Other:	·				

## Response to Arguments

The Examiner has repeated the previous rejection in order to clarify that claims 12-18 are also rejected over the Gregory reference.

Applicant's arguments filed April 03, 2006 have been fully considered but they are not persuasive.

The Applicant's representative disagree with the Examiner's point of view disclosing that the examiner has not shown sufficient evidence to establish a prima facie case of obviousness and that the Examiner misinterpreted the Gregory reference because the Gregory reference does not teach the use of a SIS sleeve. Instead the Gregory reference teaches the use of an elastin-based sleeve and never mentions small intestinal submucosa.

After a careful examination of the Applicant's remarks, the Examiner disagrees with the Applicant's point of view. The Examiner believes that the burden of establishing a prima facie case of obviousness has been proved. The Examiner believes that the motivation to combine the references, the reasonable expectation of success and all the structure limitations meet the prima facie case of obviousness.

Regarding the Gregory reference, the Examiner wants to clarify the independent claims don't disclose the use of SIS.

Regarding claims 8, 9, 17 and 18, see col. 5, lines 36-48.

The declaration under 37 CFR 1.132 filed April 03, 2006 is insufficient to overcome the rejection of claims 1 and 3-9 based upon Douglas in view of Gregory as set forth in the last Office action because: the Applicant's representative has not discloses factual evidence and has only discloses an opinion. While an opinion as to a legal conclusion is not entitled to any weight

the underlying basis for the opinion may be persuasive. In re Chilowsky, 306 F.2d 908,134 USPQ 515 (CCPA 1962).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 3-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Douglas US Patent 6,090,128 in view of Gregory US Patent 5,990,379

Douglas discloses an implant comprising a plurality of stents (42) covered by a sleeve (32, 34 & 36). The stents have proximal and a distal ends. The sleeve has a length <u>about</u> equal to twice the length of the stent (the Examiner is referring to the two stent 42 shown in Figure 2, that are folded with the sleeve 32). The sleeve has a first portion within the inside surface of the stent and a second portion that is folded back over the proximal end of the stent (see element structure 38 in Fig. 2). The second portion extends from the proximal end to the distal end, along an outside surface of the stent (see Fig. 2). Also, the first portion and the second portion are secured to at least the distal end of the stent (see Fig. 2, elements 40, 57, 59 61). Finally, Douglas discloses stents having a frame comprising eyelets at the proximal and distal ends wherein the stents are connected to each other by biocompatible filaments.

However, Douglas does not disclose a sleeve made of SIS.

Gregory teaches an implant comprising a stent (20) and a graft (16) made of extracellular matrix. The stent has a proximal end and a distal end. The sleeve has a length <u>about</u> equal to twice the length of the stent (see Figs. 8-10). The sleeve has a first portion within the inside surface of the stent and a second portion that is folded back over the proximal and distal end of the stent. The second portion extends from the proximal end to the distal end, along an outside surface of the stent (see Figs. 8-10 and col. 14, lines 31-36) for the purpose of inhibiting the

Page 4

It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the material property of the Douglas reference with the SIS sleeve of the Gregory reference in order to inhibit the migration of smooth muscle cells in the treated area.

migration of smooth muscle cells in the treated area (see col. 1, lines 22-31).

## Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 09/849,044 Page 5

Art Unit: 3738

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Alvin J. Stewart whose telephone number is 571-272-4760. The

examiner can normally be reached on Monday-Friday 7:00AM-5:30PM(1 Friday B-week off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Corrine McDermott can be reached on 571-272-4754. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALVIN J. STEWART

A. Street

September 18, 2006.